HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Harmony Biosciences Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$37.54−0.41 (-1.08%)
Close on Oct 19, 2026
- Market cap
- $2.21B
- P/E (TTM)
- 12.1
- Dividend yield
- –
Harmony Biosciences Holdings, Inc. revenue by segment
By business segment
By product or service
By region
From the segment and revenue-disaggregation notes of Harmony Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.